Nitroarylmethylcarbamate prodrugs of doxorubicin for use with nitroreductase gene-directed enzyme prodrug therapy

Bioorganic and Medicinal Chemistry

Volumn 13, Issue 12, 2005, Pages 4043-4055

  Hay, Michael P ^a   Wilson, William R ^a   Denny, William A ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Doxorubicin; Nitroreductase; Prodrug

Indexed keywords

(1 METHYL 2 NITRO 1H IMIDAZOL 5 YL)METHYLDOXORUBICIN CARBAMATE; 2 (3 HYDROXYPROPOXY) 4 NITROBENZYLDOXORUBICIN CARBAMATE; 2 METHOXY 4 NITROBENZYLDOXORUBICIN CARBAMATE; 4 [[[(1 METHYL 2 NITRO 1H IMIDAZOL 5 YL)METHOXY]CARBONYL]AMINO] BENZYLDOXORUBICIN CARBAMATE; 4 [[[(1 METHYL 5 NITRO 1H IMIDAZOL 2 YL)METHOXY]CARBONYL]AMINO] BENZYLDOXORUBICIN CARBAMATE; 4 [[[(2 METHOXY 4 NITROBENZYL)OXYL]CARBONYL]AMINO]BENZYLDOXORUBICIN CARBAMATE; 4 [[[(4 NITROBENZYL)OXYL]CARBONYL]AMINO]BENZYLDOXORUBICIN CARBAMATE; 4 NITROBENZYLDOXORUBICIN CARBAMATE; CARBAMIC ACID DERIVATIVE; DOXORUBICIN DERIVATIVE; NITROREDUCTASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CANCER; CANCER CHEMOTHERAPY; CELL LINE; CONTROLLED STUDY; DRUG CONJUGATION; DRUG RELEASE; FEMALE; GENE DIRECTED ENZYME PRODRUG THERAPY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IC 50; NONHUMAN; PHARMACEUTICAL CARE;

ANIMALS; CARBAMATES; CELL LINE; CELL SURVIVAL; DOXORUBICIN; DRUG STABILITY; GENE THERAPY; HUMANS; NITRO COMPOUNDS; NITROREDUCTASES; PRODRUGS; SOLUBILITY; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

CRICETINAE; CRICETULUS GRISEUS; MURINAE;

EID: 19444370026     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2005.03.055     Document Type: Article

References (58)

1. B.E. Huber, C.A. Richards, and E.A. Austin Adv. Drug Delivery Rev. 17 1995 279 292
2. L.-A. Martin, and N.R. Lemoine Cancer Metastasis Rev. 15 1996 301 316
3. I. Niculaescu-Duvaz, R. Spooner, R. Marais, and C.J. Springer Bioconjugate Chem. 9 1998 4 22
4. C.J. Springer, and I. Niculescu-Duvaz J. Clin. Invest. 105 2000 1161 1167
5. G. Xu, and H.L. McLeod Clin. Cancer Res. 7 2001 3314 3324
6. W.A. Denny Curr. Pharm. Des. 15 2002 1349 1361
7. G.M. Anlezark, R.G. Melton, R.F. Sherwood, B. Coles, F. Friedlos, and R.J. Knox Biochem. Pharmacol. 44 1992 2289 2296
8. R.J. Knox, F. Friedlos, R.F. Sherwood, R.G. Melton, and G.M. Anlezark Biochem. Pharmacol. 44 1992 2297 2301
9. N.P. Michael, J.K. Brehm, G.M. Anlezark, and N.P. Minton FEMS Microbiol. Lett. 124 1994 195 202
10. J.V. Skelly, P.J. Collins, R.J. Knox, G.M. Anlezark, and R.G. Melton J. Mol. Biol. 238 1994 852 853
11. J.I. Grove, P.F. Searle, S.J. Weedon, N.K. Green, I.A. McNeish, and D.J. Kerr Anti-Cancer Drug Des. 14 1999 461 472
12. A.H. Djeha, A. Hulme, M.T. Dexter, A. Mountain, L.S. Young, P.F. Searle, D.J. Kerr, and C.J. Wrighton Cancer Gene Ther. 7 2000 721 731
13. A.H. Djeha, T.A. Thomson, H. Leung, P.F. Searle, L.S. Young, D.J. Kerr, P.A. Harris, A. Mountain, and C.J. Wrighton Mol. Ther. 3 2001 233 240
14. G. Chung-Faye, C. Palmer, D. Anderson, J. Clark, M. Downes, J. Baddeley, S. Hussain, P.I. Murray, P. Searle, L. Seymour, P.A. Harris, D. Ferry, and D. Kerr J. Clin. Cancer Res. 7 2001 2662 2668
15. D.H. Palmer, V. Mautner, D. Mirza, J. Buckels, D. Olliff, D. Hull, A. Mountain, P. Harris, H. Djeha, J. Ellis, M. Horne, S. Hill, C. Wrighton, P.F. Searle, D.J. Kerr, L.S. Young, and N.D. James Br. J. Cancer 86 Suppl 1 2002 S30
16. D.H. Palmer, V. Mautner, D. Mirza, S. Oliff, W. Gerritsen, van der Sijp Jr., S. Hubscher, G. Reynolds, S. Bonney, R. Rajaratnam, D. Hull, M. Horne, J. Ellis, A. Mountain, S. Hill, P.A. Harris, P.F. Searle, L.S. Young, N.D. James, and D.J. Kerr J. Clin. Oncol. 22 2004 1546 1552
17. N.A. Helsby, G.J. Atwell, S. Yang, B.D. Palmer, R.F. Anderson, S.M. Pullen, D.M. Ferry, W.R. Wilson, and W.A. Denny J. Med. Chem. 47 2004 3295 3307
18. G.M. Anlezark, R.G. Melton, R.F. Sherwood, W.R. Wilson, W.A. Denny, B.D. Palmer, F. Friedlos, and A. Williams Biochem. Pharmacol. 50 1995 609 618
19. G.J. Atwell, M. Boyd, B.D. Palmer, R.F. Anderson, S.M. Pullen, W.R. Wilson, and W.A. Denny Anti-Cancer Drug Des. 11 1996 553 567
20. F. Friedlos, W.A. Denny, B.P. Palmer, and C.J. Springer J. Med. Chem. 40 1997 1270 1275
21. N.A. Helsby, S.J. Wheeler, F.B. Pruijn, B.D. Palmer, S. Yang, W.A. Denny, and W.R. Wilson Chem. Res. Toxicol. 16 2003 469 478
22. W.R. Wilson, S.M. Pullen, A. Hogg, N.A. Helsby, K.O. Hicks, and W.A. Denny Cancer Res. 62 2002 1425 1432
23. P.L. Carl, P.K. Chakravarty, and J.A. Katzenellenbogen J. Med. Chem. 24 1981 479 480
24. M.P. Hay, B.M. Sykes, C.J. O'Connor, and W.A. Denny J. Chem. Soc., Perkin Trans. 1 1999 2759 2770
25. B.M. Sykes, M.P. Hay, D. Bohinc-Herceg, W.A. Denny, and C.J. O'Connor J. Chem. Soc., Perkin Trans. 1 2000 1601 1608
26. A.B. Mauger, P.J. Burke, H.H. Somani, F. Friedlos, and R.J. Knox J. Med. Chem. 37 1994 3452 3458
27. M.P. Hay, W.R. Wilson, and W.A. Denny Bioorg. Med. Chem. Lett. 5 1995 2829 2834
28. M.P. Hay, W.R. Wilson, and W.A. Denny Bioorg. Med. Chem. Lett. 9 1999 3417 3422
29. M. Tercel, W.A. Denny, and W.R. Wilson Bioorg. Med. Chem. Lett. 6 1996 2741 2744
30. M.J. Sagnou, P.W. Howard, S.J. Gregson, E. Eno-Amooquaye, P.J. Burke, and D.E. Thurston Bioorg. Med. Chem. Lett. 10 2000 2083 2086
31. M. Lee, J.E. Simpson Jr., S. Woo, C. Kaenzig, G.M. Anlezark, E. Eno-Amooquaye, and P.J. Burke Bioorg. Med. Chem. Lett. 7 1997 1065 1070
32. R.T. Mulcahy, J.J. Gipp, J.P. Schmidt, C. Joswig, and R.F. Borch J. Med. Chem. 37 1994 1610 1615
33. L. Hu, C. Yu, Y. Jiang, J. Han, Z. Li, P. Browne, P.R. Race, R.J. Knox, P.F. Searle, and E.I. Hyde J. Med. Chem. 46 2003 4818 4821
34. M.P. Hay, G.J. Atwell, W.R. Wilson, S.M. Pullen, and W.A. Denny J. Med. Chem. 46 2003 2456 2466
35. M.P. Hay, B.M. Sykes, W.A. Denny, and W.R. Wilson Bioorg. Med. Chem. Lett. 9 1999 2237 2242
36. M.P. Hay, R.F. Anderson, D.M. Ferry, W.R. Wilson, and W.A. Denny J. Med. Chem. 46 2003 5533 5545
37. L.N. Jungheim, and T.A. Shepherd Chem. Rev. 94 1994 1553 1566
38. M.P. Hay, and W.A. Denny Drugs Future 21 1996 917 931
39. C.J. Springer, and I. Niculescu-Duvaz Expert Opin. Invest. Drugs 3 1996 289 308
40. W.A. Denny Curr. Pharm. Des. 2 1996 281 294
41. S. Papot, I. Tranoy, F. Tillequin, J.-C. Florent, and J.-P. Gesson Curr. Med. Chem.-Anti-Cancer Agents 2 2002 155 185
42. M. Rooseboom, J.N.M. Commandeur, and N.P.E. Vermeulen Pharmacol. Rev. 56 2004 53 102
43. H.J. Haisma, M. van Muijen, H.M. Pinedo, and E. Boven Cell Biophys. 24/25 1994 185 192
44. M. Azoulay, J.-C. Florent, C. Monneret, J.P. Gesson, J.-C. Jacquesy, F. Tillequin, M. Koch, K. Bosslet, J. Czech, and D. Hoffman Anti-Cancer Drug Des. 10 1995 441 450
45. P.H.J. Houba, R.G.G. Leenders, E. Boven, J.W. Scheeren, H.M. Pinedo, and H.J. Haisma Biochem. Pharmacol. 52 1996 455 563
46. R.G.G. Leenders, E.W.P. Damen, E.J.A. Bijsterveld, H.W. Scheeren, I.H. van der Meulen-Muileman, E. Boven, and H.J. Haisma Bioorg. Med. Chem. 7 1999 1597 1610
47. G.M. Dubowchik, and R.A. Firestone Bioorg. Med. Chem. Lett. 8 1998 3341 3346
48. G.M. Dubowchik, K. Mosure, J.O. Knipe, and R.A. Firestone Bioorg. Med. Chem. Lett. 8 1998 3341 3346
49. M.P. Hay, W.R. Wilson, and W.A. Denny Tetrahedron 56 2000 645 657
50. G.M. Dubrovchik, H.D. King, and K. Pham-Kaplita Tetrahedron Lett. 38 1997 5261 5264
51. W.R. Wilson, S.M. Pullen, A. Hogg, S.M. Hobbs, F.B. Pruijn, and K.O. Hicks C.J. Springer Suicide Gene Therapy: Methods and Protocols for Cancer 2003 Humana Totowa, NJ 403 432
52. B.G. Siim, A.E. Lee, S. Shalal-Zwain, F.B. Pruijn, M.J. McKeage, and W.R. Wilson Cancer Chemother. Pharmacol. 51 2003 43 52
53. C.A. Lipinski J. Pharmacol. Toxicol. Method 44 2000 235 249
54. A.H. Kyle, L.A. Huxham, A.S.J. Chiam, D.H. Sim, and A.I. Minchinton Cancer Res. 64 2004 6304 6309
55. R.E. Durand Cancer Chemother. Pharmacol. 26 1990 198 204
56. F. Friedlos, S. Court, M. Ford, W.A. Denny, and C.J. Springer Gene Ther. 5 1998 105 112
57. G.J. Finlay, B.C. Baguley, and W.R. Wilson Anal. Biochem. 139 1984 272 277
58. B.D. Palmer, W.R. Wilson, R.F. Anderson, M. Boyd, and W.A. Denny J. Med. Chem. 39 1996 2518 2528